bullish
Hansoh Pharma's HS-10296 - How Far Is It From Billion $ Tagrisso? Our Read on Phase 2 Reports
448 Views10 Oct 2019 09:33
Hansoh Pharma, a leading China-based pharmaceutical company, recorded a stellar post-IPO performance since its listing in June. As a big portion of...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- Hansoh Pharma Placement - Good Stock but Valuation and No Lack of Cash Makes It Appear Opportunistic21 Apr 2020
- Hansoh Pharma's Lock-Up Expiry: Valuation and the Trade05 Dec 2019
- Hansoh Pharma's Lock-Up Expiry - New Drugs Offset the Impact of Centralized Procurement04 Dec 2019
- Hansoh Pharma's HS-10296 - How Far Is It From Billion $ Tagrisso? Our Read on Phase 2 Reports10 Oct 2019
- Hansoh Pharma (翰森制药) Post-IPO Trading Update: Fairly Valued17 Jun 2019
- Hansoh Pharma (翰森制药) IPO: Strong Cornerstone Line-Up, Upside at Low End30 May 2019
x